CClinicalTrials.gg
CompletedNCT05047978Updated Jan 23, 2024

Growth and Tolerance of a Partially Hydrolyzed Infant Formula

An interventional study of Cow's milk protein infant formula and Partially hydrolyzed protein infant formula in Growth, sponsored by Mead Johnson Nutrition. Completed at 13 sites in United States. Open to participants aged 10 Days to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Mead Johnson Nutrition · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
10 Days to 14 Days
Sex
All
01

Study summary

The purpose of this research study is to compare the growth and tolerance of infants who consume either an infant formula with intact proteins or an infant formula with partially hydrolyzed proteins through approximately 12 months of age.

02

Conditions studied

  • Growth
03

In context

Lead sponsor

Mead Johnson Nutrition is the lead sponsor of 56 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Days to 14 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 10 to 14 days of age at randomization
  • singleton birth
  • Gestational age of 37 to 42 weeks
  • Birth weight of 2500 g (5lbs 8oz or more)
  • Exclusively receiving infant formula for at least 24 hours prior to randomization
  • Parent or legal guardian has full intention to exclusively feed study formula through 120 days of age
  • Parent or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study
  • Signed informed consent and authorization to use and disclose Protected Health information

Exclusion criteria

Exclusion Criteria:

  • History of underlying metabolic or chronic disease
  • Evidence of feeding difficulties or history of formula intolerance
  • Weight at Visit 1 is \<98% of birth weight
  • Infant was born large for gestational age from a mother who was diabetic at childbirth
  • Infant is immunocompromised
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
244 participants (actual)

Study arms

  • Active comparator
    A routine cow's milk-based infant formula

    A routine cow's milk-based infant formula

    Other: Cow's milk protein infant formula

  • Experimental
    A partially hydrolyzed cow's milk protein (PHP) infant formula

    A partially hydrolyzed cow's milk protein (PHP) infant formula

    Other: Partially hydrolyzed protein infant formula

Interventions

  • OtherCow's milk protein infant formula

    A routine cow's milk-based infant formula

  • OtherPartially hydrolyzed protein infant formula

    A partially hydrolyzed cow's milk protein (PHP) infant formula

06

What researchers measure

Primary outcomes

  1. Rate of body weight gain

    Time frame: up to 120 days

Secondary outcomes

  1. Body length

    Time frame: up to 365 days of age

  2. Head circumference

    Time frame: up to 365 days of age

  3. Growth Z scores

    weight-for-age

    Time frame: up to 365 days of age

  4. Growth Z scores

    length-for-age

    Time frame: up to 365 days of age

  5. Growth Z scores

    head circumference-for-age

    Time frame: up to 365 days of age

  6. Recall of study formula intake measured at each study visit

    questionnaire

    Time frame: up to 365 days of age

  7. Recall of stool characteristics measured at each study visit

    questionnaire

    Time frame: up to 365 days of age

  8. Pediatric Quality of Life Family Impact Module

    questionnaire

    Time frame: up to 365 days of age

  9. Pediatric Quality of Life Inventory Infant Scales

    Questionnaire. A 5-point response scale is utilized (0 = never a problem; 4 = always a problem). Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).

    Time frame: 120, 180, 275, and 365 days of age

  10. Medically confirmed adverse events collected throughout the study period

    Time frame: up to 365 days of age

  11. Specific medically confirmed adverse events related to gastrointestinal

    Time frame: up to 365 days of age

  12. Specific medically confirmed adverse events related to allergy

    Time frame: up to 365 days of age

  13. Body weight

    Time frame: up to 365 days of age

07

Study locations

13 sites
  • Birmingham Pediatric Associates
    Birmingham, Alabama 35205, United States
  • Southeastern Pediatric Associates
    Dothan, Alabama 36305, United States
  • Visions Clinical Research-Tucson
    Tucson, Arizona 85712, United States
  • Northwest Arkansas Pediatric Clinic
    Fayetteville, Arkansas 72703, United States
  • The Children's Clinic of Jonesboro
    Jonesboro, Arkansas 72401, United States
  • PAS Research
    Tampa, Florida 33613, United States
  • Rophe Adult & Pediatric Medicine
    Union City, Georgia 30339, United States
  • Saltzer Health
    Nampa, Idaho 83686, United States
  • Springs Medical Research
    Owensboro, Kentucky 42303, United States
  • Meridian Clinical Research
    Grand Island, Nebraska 68803, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • PAS Research
    McAllen, Texas 78501, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05047978
Lead sponsor
Mead Johnson Nutrition
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Aug 28, 2021
Primary completion
Oct 11, 2022
Completion
Nov 21, 2023
Last update
Jan 23, 2024

Study contacts

Steven Wu, Medical Director
study director · Mead Johnson Nutrition

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion